Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/ BCR-FGFR1 -rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib
Manur, Rashmi, Sung, Pamela J., Loren, Alison W., Ritchie, Ellen K., Frank, Dale, Bagg, Adam, Geyer, Julia T., Bogusz, Agata M.Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2019.1660975
Date:
September, 2019
File:
PDF, 1.14 MB
english, 2019